Half price

The formula of the medicine is currently being prepared by the Pharmaceutical Institute (IF), the largest domestic medical research center. "It will be a generic drug, whose counterpart is already available in Poland, but it is very expensive. Our product will be half the price," said Wiesław Szelejewski, head of the Institute. He believes that Bioton will be able to provide the drug to a wider group of diabetics, as it can be used in treating the first stage of the illness. Bioton hopes to be able to sell the drug throughout Eastern Europe and Asia.